Gilead Sciences Livdelzi revenue
Livdelzi revenue at Gilead Sciences came to $203.0M for the quarter to 30 Sep 2026, up 93.3% from a year earlier.
As Gilead Sciences reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 30 Oct 2026.
By quarter
| Period ending | Livdelzi revenue | Change on a year | Filed |
|---|---|---|---|
| 30 Sep 2026 | $203.0M | up 93.3% | 30 Oct 2026 |
| 30 Jun 2026 | $167.0M | up 114.1% | 6 Aug 2026 |
| 31 Mar 2026 | $133.0M | up 232.5% | 7 May 2026 |
| 30 Sep 2025 | $105.0M | — | 7 Nov 2025 |
| 30 Jun 2025 | $78.0M | — | 7 Aug 2025 |
| 31 Mar 2025 | $40.0M | — | 7 May 2025 |
Definition
Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.
Other operating KPIs of Gilead Sciences: Product sales · Biktarvy revenue · Descovy revenue · Trodelvy revenue · Genvoya revenue · Vemlidy revenue · Yeztugo revenue · Yescarta revenue · Odefsey revenue · Sofosbuvir/Velpatasvir revenue · Symtuza - Revenue share revenue · AmBisome revenue · Veklury revenue · Tecartus revenue · Royalty, contract and other revenues · United States revenue · Europe revenue · Rest of World revenue · financial statements
Every KPI and segment of GILD, in the terminal.
Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.
